Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V

Table 2 Incidence of thromboembolic events

Outcome	Edoxaban 30 mg QD (n = 255)		Enoxaparin 2000 IU BID (n = 248)		Absolute difference % (95 % CI)
Outcome	n (%)	95 % CI	n (%)	95 % CI	Absolute difference % (95 % CI)
Primary efficacy (any VTE)	6 (2.4)	1.1, 5.0	17 (6.9)	4.3, 10.7	−4.5 (−8.6, −0.9)^a,b
Asymptomatic DVT
Total^c	6 (2.4)	1.1, 5.0	17 (6.9)	4.3, 10.7	−4.5 (−8.6, −0.9)
Proximal	1 (0.4)	0.1, 2.2	2 (0.8)	0.2, 2.9	−0.4 (−2.5, 1.5)
Distal	6 (2.4)	1.1, 5.0	16 (6.5)	4.0, 10.2	−4.1 (−8.1, −0.6)
Symptomatic DVT	0 (0.0)	0.0, 1.5	0 (0.0)	0.0, 1.5	0.0
Symptomatic PE	0 (0.0)	0.0, 1.5	0 (0.0)	0.0, 1.5	0.0
VTE-related death	0 (0.0)	0.0, 1.5	0 (0.0)	0.0, 1.5	0.0
Symptomatic DVT, proximal DVT, symptomatic PE, or VTE-related death	1 (0.4)	0.1, 2.2	2 (0.8)	0.2, 2.9	−0.4 (−2.5, 1.5)

BID, twice daily; CI, confidence interval; DVT, deep vein thrombosis; IU, international unit; PE, pulmonary embolism; QD, once daily; VTE, venous thromboembolism
^a p <0.001 as calculated by the noninferiority Farrington-Manning test; ^b p = 0.0157 as calculated by the superiority Farrington-Manning test; ^cone patient had both a proximal and a distal DVT

ISSN: 1477-9560